![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, Abbott Park, Illinois (G.B.F., T.A.E., J.B.P., R.J.R., K.M.K., B.B.Y., K.E.B., M.J.B., M.E.B., V.A.K., H.M., M.Z., R.F., L.E.R., R.S.B., J.W., K.M., J.P.S., M.D.C., M.W.D., A.A.H.); Neuroscience Research, Global Pharmaceutical Research Division, Abbott/GmbH and Co., Ludwigshafen, Germany (K.U.D.); Porsolt and Partners Pharmacology, Boulogne-Billancourt, France (M.L., R.D.P.); and Vertex Pharmaceuticals, Cambridge, Massachusetts (Y.L.B.)
Acute pharmacological blockade of central histamine H3 receptors (H3Rs) enhances arousal/attention in rodents. However, there is little information available for other behavioral domains or for repeated administration using selective compounds. ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] exemplifies such a selective, nonimidazole H3R antagonist with high affinity for rat (pKi = 8.9) and human (pKi = 9.5) H3Rs. Acute functional blockade of central H3 Rs was demonstrated by blocking the dipsogenia response to the selective H3R agonist (R)-
-methylhistamine in mice. In cognition studies, acquisition of a five-trial, inhibitory avoidance test in rat pups was improved with ABT-239 (0.1–1.0 mg/kg), a 10- to 150-fold gain in potency, with similar efficacy, over previous antagonists such as thioperamide, ciproxifan, A-304121 [(4-(3-(4-((2R)-2-aminopropanoyl)-1-piperazinyl)propoxy)phenyl)(cyclopropyl) methanone], A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl) phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide], and A-349821 [(4'-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)-morpholin-4-yl-methanone]. Efficacy in this model was maintained for 3 to 6 h and following repeated dosing with ABT-239. Social memory was also improved in adult (0.01–0.3 mg/kg) and aged (0.3–1.0 mg/kg) rats. In schizophrenia models, ABT-239 improved gating deficits in DBA/2 mice using prepulse inhibition of startle (1.0–3.0 mg/kg) and N40 (1.0–10.0 mg/kg). Furthermore, ABT-239 (1.0 mg/kg) attenuated methamphetamine-induced hyperactivity in mice. In freely moving rat microdialysis studies, ABT-239 enhanced acetylcholine release (0.1–3.0 mg/kg) in adult rat frontal cortex and hippocampus and enhanced dopamine release in frontal cortex (3.0 mg/kg), but not striatum. In summary, broad efficacy was observed with ABT-239 across animal models such that potential clinical efficacy may extend beyond disorders such as ADHD to include Alzheimer's disease and schizophrenia.
Address correspondence to: Dr. Gerard B. Fox, Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, AP9A, R4N5, Abbott Park, IL 60064-6115. E-mail: gerard.b.fox{at}abbott.com
This article has been cited by other articles:
|
|
 |
|
  H. L. Haas, O. A. Sergeeva, and O. Selbach Histamine in the Nervous System Physiol Rev, July 1, 2008; 88(3): 1183 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Le, J. A. Gruner, J. R. Mathiasen, M. J. Marino, and H. Schaffhauser Correlation between ex Vivo Receptor Occupancy and Wake-Promoting Activity of Selective H3 Receptor Antagonists J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 902 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Medhurst, A. R. Atkins, I. J. Beresford, K. Brackenborough, M. A. Briggs, A. R. Calver, J. Cilia, J. E. Cluderay, B. Crook, J. B. Davis, et al. GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1032 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ligneau, D. Perrin, L. Landais, J.-C. Camelin, T. P. G. Calmels, I. Berrebi-Bertrand, J.-M. Lecomte, R. Parmentier, C. Anaclet, J.-S. Lin, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, Hydrochloride], a Nonimidazole Inverse Agonist/Antagonist at the Human Histamine H3 Receptor: Preclinical Pharmacology J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Esbenshade, G. B. Fox, and M. D. Cowart Histamine h3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv., April 1, 2006; 6(2): 77 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Canonaco, M. Madeo, R. Alo, G. Giusi, T. Granata, A. Carelli, A. Canonaco, and R. M. Facciolo The Histaminergic Signaling System Exerts a Neuroprotective Role against Neurodegenerative-Induced Processes in the Hamster J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 188 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Hagan and D. N C Jones Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia Schizophr Bull, October 1, 2005; 31(4): 830 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Esbenshade, G. B. Fox, K. M. Krueger, T. R. Miller, C. H. Kang, L. I. Denny, D. G. Witte, B. B. Yao, L. Pan, J. Wetter, et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 165 - 175. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
